


(R)-Asundexian

Cat. No.:	HY-137431A		
CAS No.:	2064124-85-0		
Molecular Formula:	C ₂₆ H ₂₁ ClF ₄ N ₆ O ₄		
Molecular Weight:	592.93		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (421.63 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.6865 mL	8.4327 mL	16.8654 mL
5 mM	0.3373 mL	1.6865 mL	3.3731 mL
10 mM	0.1687 mL	0.8433 mL	1.6865 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(R)-Asundexian ((R)-BAY-2433334) is the enantiomer of [Asundexian](#) (HY-137431). (R)-Asundexian can be used in studies of cardiovascular disease (especially thrombotic or thromboembolic disease), edema, and ophthalmic disease^[1].

REFERENCES

- [1]. Jimenez Nunez Eloisa, et al. Preparation of substituted oxopyridine derivatives for the treatment and/or prophylaxis of diseases. Patent WO2017005725A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA